Skip to main content
Fig. 6 | Stem Cell Research & Therapy

Fig. 6

From: The therapeutic efficacy of mesenchymal stromal cells on experimental colitis was improved by the IFN-γ and poly(I:C) priming through promoting the expression of indoleamine 2,3-dioxygenase

Fig. 6

Pharmacologic IDO1 inhibition decreased the immune-modulatory effects of the IFN-γ and poly(I:C)-primed MSC. a Experimental colitis was induced, and the unstimulated or primed MSCs were administered as described in Fig. 1. The competitive IDO inhibitor, L-1MT (200 mg/kg), was administered by oral gavage from day 1 to day 5. All mice were followed up daily and sacrificed on day 9 to harvest colon tissues. Representative data of two independent experiments are presented (n = 5 for each group). b Daily body weight. c Daily DAI score (DSS vs. DSS + primed MSC, *p < 0.05, **p < 0.01, ***p < 0.001; DSS + primed MSC + L-1MT vs. DSS + primed MSC, #p < 0.05, ##p < 0.01, ###p < 0.001). d Colon lengths were measured on day 9. e Results of quantitative PCR from colon tissue demonstrated that the oral L-1MT administration reversed the expression of Foxp3 and IDO1, which was increased by the primed MSC treatment. Representative data of two independent experiments are presented (n = 5 for each group) (*p < 0.05, **p < 0.01, ***p < 0.001)

Back to article page